secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2025-10-24T23:59:59+00:00
Accession:  0001104659-25-102104
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics files prospectus supplement for up to $4.02M ATM offering of common stock
--------------------------------------------------------------------------------

- Up to $4,019,597 of common stock may be sold through A.G.P./Alliance Global Partners as sales agent.
- Sales will be at-the-market under Rule 415(a)(4); agent receives up to 3% commission.
- Shares offered under existing S-3 shelf (File No. 333-279077) effective September 25, 2024.
- No minimum sales obligation; company retains discretion over timing and amount.
- Legal opinion on share validity from Parsons Behle & Latimer filed as Exhibit 5.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465925102104/0001104659-25-102104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465925102104/tm2529425d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-102104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer